{"id":"W2051878959","doi":"10.3816/cbc.2010.n.023","title":"Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer","year":2010,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Eribulin; Medicine; Metastatic breast cancer; Capecitabine; Internal medicine; Oncology; Anthracycline; Breast cancer; Taxane; Clinical endpoint; Cancer; Randomized controlled trial; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001277045,0.001316365,0.002016032,0.0004893055,0.0003824383,0.0007077398,0.0008235851,0.000852509,0.004244365],"category_scores_gemma":[0.0007303701,0.0004628435,0.0008533229,0.0006069237,0.0007486274,0.0006957249,0.0003667589,0.002405059,0.000974905],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007181246,"about_ca_system_score_gemma":0.001095003,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001644816,"about_ca_topic_score_gemma":0.006050619,"domain_scores_codex":[0.999569,0.0002349844,0.00001520533,0.00003518447,0.00002538059,0.0001202378],"domain_scores_gemma":[0.9995808,0.00008838607,0.00007433737,0.00003387,0.00001974953,0.0002027912],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6452221,0.04084956,0.007992032,0.0008910375,0.001648952,0.0003879968,0.000381647,0.004750662,0.05120087,0.0009820673,0.008560452,0.2371326],"study_design_scores_gemma":[0.5458852,0.4147562,0.02205716,0.00007305272,0.0007359301,0.0004982791,0.0001697589,0.001573984,0.006048313,0.0005081262,0.007655203,0.00003882773],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878011,0.004116989,0.000523755,0.0007577803,0.000139532,0.001412309,0.001144602,0.000118555,0.003985394],"genre_scores_gemma":[0.9859614,0.004488172,0.001195061,0.0008439315,0.0001752755,0.001220539,0.00223301,0.00004686293,0.003835792],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004244365,"threshold_uncertainty_score":0.01419878,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08561982642156016,"score_gpt":0.4677892660465072,"score_spread":0.382169439624947,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}